Chrysostomi Gialeli
Chrysostomi Gialeli
Lund University Department of Translational Medicine Malmö, Division of Medical Protein Chemistry
Email verificata su med.lu.se
Titolo
Citata da
Citata da
Anno
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
C Gialeli, AD Theocharis, NK Karamanos
The FEBS journal 278 (1), 16-27, 2011
13532011
Extracellular matrix structure
AD Theocharis, SS Skandalis, C Gialeli, NK Karamanos
Advanced drug delivery reviews 97, 4-27, 2016
7082016
Glycosaminoglycans: key players in cancer cell biology and treatment#
N Afratis, C Gialeli, D Nikitovic, T Tsegenidis, E Karousou, AD Theocharis, ...
FEBS Journal, 2012
3972012
Cell–matrix interactions: focus on proteoglycan–proteinase interplay and pharmacological targeting in cancer
AD Theocharis, C Gialeli, P Bouris, E Giannopoulou, SS Skandalis, ...
The FEBS journal 281 (22), 5023-5042, 2014
802014
Emerging aspects of nanotoxicology in health and disease: from agriculture and food sector to cancer therapeutics
Z Piperigkou, K Karamanou, AB Engin, C Gialeli, AO Docea, DH Vynios, ...
Food and Chemical Toxicology 91, 42-57, 2016
772016
Syndecans as modulators and potential pharmacological targets in cancer progression
D Barbouri, N Afratis, C Gialeli, DH Vynios, AD Theocharis, N Karamanos
Frontiers in oncology 4, 4, 2014
712014
Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid
PG Dedes, C Gialeli, AI Tsonis, I Kanakis, AD Theocharis, D Kletsas, ...
Biochimica et Biophysica Acta (BBA)-General Subjects 1820 (12), 1926-1939, 2012
652012
Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin‐like growth factor receptor in the expression of cell surface …
AI Tsonis, N Afratis, C Gialeli, MI Ellina, Z Piperigkou, SS Skandalis, ...
The FEBS journal 280 (10), 2248-2259, 2013
552013
Imatinib as a key inhibitor of the platelet‐derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast …
CJ Malavaki, AE Roussidis, C Gialeli, D Kletsas, T Tsegenidis, ...
The FEBS journal 280 (10), 2477-2489, 2013
482013
Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies
CH Gialeli, D Kletsas, D Mavroudis, HP Kalofonos, GN Tzanakakis, ...
Current medicinal chemistry 16 (29), 3797-3804, 2009
372009
PDGF/PDGFR signaling and targeting in cancer growth and progression: focus on tumor microenvironment and cancer-associated fibroblasts
C Gialeli, D Nikitovic, D Kletsas, A D Theocharis, G N Tzanakakis, ...
Current pharmaceutical design 20 (17), 2843-2848, 2014
362014
Advances and advantages of nanomedicine in the pharmacological targeting of hyaluronan-CD44 interactions and signaling in cancer
SS Skandalis, C Gialeli, AD Theocharis, NK Karamanos
Advances in cancer research 123, 277-317, 2014
282014
Inhaled chemotherapy in lung cancer: safety concerns of nanocomplexes delivered
P Zarogoulidis, C Gialeli, NK Karamanos
Therapeutic delivery 3 (9), 1021-1023, 2012
272012
Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab
C Gialeli, AD Theocharis, D Kletsas, GN Tzanakakis, NK Karamanos
Investigational new drugs 31 (3), 516-524, 2013
242013
The role of oligodendrocytes in the molecular pathobiology and potential molecular treatment of cervical spondylotic myelopathy
SK Karadimas, CH Gialeli, G Klironomos, GN Tzanakakis, ...
Current medicinal chemistry 17 (11), 1048-1058, 2010
232010
Extracellular matrix: a functional scaffold
AD Theocharis, C Gialeli, V Hascall, NK Karamanos
Extracellular Matrix: Pathobiology and Signaling; Karamanos, NK, Ed.; Walter …, 2012
202012
Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer
A Escudero-Esparza, M Bartoschek, C Gialeli, M Okroj, S Owen, ...
Oncotarget 7 (47), 76920, 2016
192016
Synthesis and Εvaluation of Αnticancer Αctivity in Cells of Novel Stoichiometric Pegylated Fullerene-Doxorubicin Conjugates
GE Magoulas, M Bantzi, D Messari, E Voulgari, C Gialeli, D Barbouri, ...
Pharmaceutical research 32 (5), 1676-1693, 2015
192015
Preparation and Toxicological Assessment of Functionalized Carbon Nanotube-Polymer Hybrids
JK Koromilas, N. D., Lainioti, G., Gialeli, C., Barbouri, D., Kouravelou, K ...
PLoS One. 9, e107029., 2014
19*2014
Targeting the tumor proteasome as a mechanism to control the synthesis and bioactivity of matrix macromolecules.
KNK Skandalis SS, Aletras AJ, Gialeli C, Theocharis AD
Curr Mol Med, 2012
172012
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20